Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.

Tytuł :
Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
Autorzy :
Afshari A; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Janfeshan S; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Yaghobi R; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Roozbeh J; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: .
Azarpira N; Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Pokaż więcej
Źródło :
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases [Infect Genet Evol] 2021 Mar; Vol. 88, pp. 104669. Date of Electronic Publication: 2020 Dec 07.
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
MeSH Terms :
Angiotensin-Converting Enzyme 2/*genetics
COVID-19/*genetics
Oncogene Proteins, Fusion/*genetics
Prostatic Neoplasms/*genetics
Serine Endopeptidases/*genetics
Spike Glycoprotein, Coronavirus/*genetics
Aged ; Angiotensin-Converting Enzyme 2/metabolism ; COVID-19/complications ; COVID-19/pathology ; COVID-19/virology ; Dihydrotestosterone/metabolism ; Gene Expression Regulation ; Host-Pathogen Interactions/genetics ; Humans ; Male ; Oncogene Proteins, Fusion/metabolism ; Prostatic Neoplasms/complications ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/virology ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; SARS-CoV-2/genetics ; SARS-CoV-2/metabolism ; SARS-CoV-2/pathogenicity ; Serine Endopeptidases/metabolism ; Signal Transduction ; Spike Glycoprotein, Coronavirus/metabolism ; Transcription, Genetic ; Virus Internalization
References :
J Exp Med. 2005 Aug 1;202(3):415-24. (PMID: 16043521)
PLoS Pathog. 2019 May 16;15(5):e1007756. (PMID: 31095648)
J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97. (PMID: 11717329)
Internist (Berl). 2019 Nov;60(11):1136-1145. (PMID: 31455974)
Cancer Biol Ther. 2005 Jan;4(1):4-5. (PMID: 16052746)
Lancet. 2020 Feb 15;395(10223):514-523. (PMID: 31986261)
Genomics. 1997 Sep 15;44(3):309-20. (PMID: 9325052)
Eur Urol. 2014 Mar;65(3):534-42. (PMID: 23201468)
J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201. (PMID: 12163131)
J Virol. 2015 Oct;89(19):10073-86. (PMID: 26202252)
Annu Rev Med. 2017 Jan 14;68:387-399. (PMID: 27576010)
Cancer Res. 1999 Sep 1;59(17):4180-4. (PMID: 10485450)
Epigenetics. 2012 Aug;7(8):940-9. (PMID: 22805767)
Nat Rev Cancer. 2012 May 11;12(6):425-36. (PMID: 22576165)
Cent European J Urol. 2018;71(4):410-419. (PMID: 30680235)
Nat Genet. 2009 May;41(5):619-24. (PMID: 19396168)
J Cell Biochem. 2006 Oct 1;99(2):333-44. (PMID: 16518832)
Lancet. 2020 Feb 15;395(10223):470-473. (PMID: 31986257)
PLoS One. 2018 Jan 11;13(1):e0191010. (PMID: 29324866)
Mol Med Rep. 2012 Feb;5(2):313-6. (PMID: 22038307)
Stem Cells. 2008 Jul;26(7):1695-704. (PMID: 18420831)
Oncogene. 2007 Apr 19;26(18):2667-73. (PMID: 17043636)
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. (PMID: 14974761)
Front Neuroendocrinol. 2001 Jul;22(3):185-212. (PMID: 11456468)
Cancer Cell. 2011 May 17;19(5):664-78. (PMID: 21575865)
Biomed Microdevices. 2013 Dec;15(6):907-15. (PMID: 23813077)
Eur J Cancer. 1997 Apr;33(4):545-54. (PMID: 9274433)
Endocr Rev. 2004 Apr;25(2):276-308. (PMID: 15082523)
Gastroenterology. 2011 Dec;141(6):2076-2087.e6. (PMID: 21925125)
Annu Rev Biochem. 2001;70:81-120. (PMID: 11395403)
J Cosmet Dermatol. 2020 Jul;19(7):1545-1547. (PMID: 32301221)
BMC Cancer. 2011 Dec 05;11:507. (PMID: 22142399)
J Infect Dis. 2006 Mar 15;193(6):792-5. (PMID: 16479513)
Nature. 2003 Nov 27;426(6965):450-4. (PMID: 14647384)
J Clin Oncol. 2014 Jan 20;32(3):206-11. (PMID: 24297949)
Oncogene. 2013 Jan 17;32(3):277-85. (PMID: 22391564)
Cancer Res. 2009 Mar 15;69(6):2210-8. (PMID: 19258514)
J Virol. 2012 Jun;86(12):6537-45. (PMID: 22496216)
Int J Cancer. 2013 Feb 15;132(4):775-84. (PMID: 22815235)
Semin Surg Oncol. 2000 Jan-Feb;18(1):52-74. (PMID: 10617897)
Cancer Res. 2009 Sep 15;69(18):7165-9. (PMID: 19738047)
Nat Rev Urol. 2009 Aug;6(8):429-39. (PMID: 19657377)
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81. (PMID: 16081529)
Cancer Res. 2010 Dec 1;70(23):9544-8. (PMID: 20947519)
Nat Med. 2004 Jan;10(1):33-9. (PMID: 14702632)
Oncol Rep. 2012 Apr;27(4):1019-26. (PMID: 22267008)
Biochem Pharmacol. 2012 Apr 15;83(8):1013-20. (PMID: 22192819)
Oncogene. 2014 Apr 24;33(17):2204-14. (PMID: 23708657)
Carcinogenesis. 2012 Dec;33(12):2558-67. (PMID: 23027626)
Cancer Res. 2001 Feb 15;61(4):1686-92. (PMID: 11245484)
Cancer Res. 2006 Nov 15;66(22):10658-63. (PMID: 17108102)
J Virol. 2010 Dec;84(24):12658-64. (PMID: 20926566)
J Biol Chem. 2011 Dec 2;286(48):41442-54. (PMID: 21971048)
Cancer Discov. 2012 Nov;2(11):1024-35. (PMID: 22930729)
Mod Pathol. 2012 Mar;25(3):471-9. (PMID: 22080055)
Int J Urol. 2014 Dec;21(12):1234-8. (PMID: 25040002)
Antiviral Res. 2015 Apr;116:76-84. (PMID: 25666761)
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14. (PMID: 18490652)
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63. (PMID: 10318905)
Eur Respir J. 2015 Jun;45(6):1745-8. (PMID: 25745039)
J Virol. 2020 Feb 14;94(5):. (PMID: 31801868)
Cancer Res. 2011 Aug 15;71(16):5387-92. (PMID: 21676887)
Prostate. 2013 May;73(6):596-604. (PMID: 23060044)
Nat Rev Microbiol. 2016 Aug;14(8):523-34. (PMID: 27344959)
J Infect. 2020 Jun;80(6):607-613. (PMID: 32283152)
Cancer Metastasis Rev. 2001;20(3-4):207-23. (PMID: 12085963)
Science. 2005 Sep 16;309(5742):1864-8. (PMID: 16166518)
Nat Rev Cancer. 2001 Oct;1(1):55-67. (PMID: 11900252)
J Clin Endocrinol Metab. 1989 Feb;68(2):461-8. (PMID: 2465302)
Hum Mol Genet. 2012 Jul 15;21(14):3112-27. (PMID: 22505583)
FEBS Lett. 2012 May 7;586(9):1279-86. (PMID: 22465665)
PLoS One. 2011;6(7):e21650. (PMID: 21747944)
J Virol. 2019 Mar 5;93(6):. (PMID: 30626688)
Cancer Res. 2012 Jul 15;72(14):3618-30. (PMID: 22552290)
J Clin Endocrinol Metab. 2003 Jul;88(7):2972-82. (PMID: 12843129)
J Pathol. 2012 Jul;227(3):275-85. (PMID: 22262409)
Am J Cancer Res. 2011;1(5):604-17. (PMID: 21994901)
Viruses. 2018 Jul 26;10(8):. (PMID: 30049972)
Mol Cell Biol. 2006 Feb;26(3):965-75. (PMID: 16428450)
J Biol Chem. 2009 Sep 11;284(37):24696-704. (PMID: 19584056)
J Biol Chem. 2012 Jan 6;287(2):1527-37. (PMID: 22128178)
PLoS One. 2011;6(11):e28162. (PMID: 22140532)
Cancer Cell. 2010 May 18;17(5):443-54. (PMID: 20478527)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Cancer. 1993 May 1;71(9):2782-90. (PMID: 7682149)
Nat Rev Cancer. 2012 Apr 19;12(5):323-34. (PMID: 22513401)
Endocr Rev. 2002 Apr;23(2):175-200. (PMID: 11943742)
Cancer Cell Int. 2014 Apr 17;14:34. (PMID: 24739220)
Nat Rev Cancer. 2001 Oct;1(1):34-45. (PMID: 11900250)
Cell Microbiol. 2007 Oct;9(10):2358-71. (PMID: 17848167)
Epigenetics. 2011 Oct 1;6(10):1248-56. (PMID: 21946329)
J Virol. 2013 May;87(10):5502-11. (PMID: 23468491)
Biotechnol Adv. 2013 Nov 15;31(7):1094-107. (PMID: 23906838)
Cancer Res. 2006 Jun 1;66(11):5723-8. (PMID: 16740710)
Clin Cancer Res. 2005 Mar 1;11(5):1704-12. (PMID: 15755991)
J Pathol. 2012 Jul;227(3):336-45. (PMID: 22431170)
Contributed Indexing :
Keywords: Cancer*; Fusion*; Prostate*; SARS-CoV-2*; TMPRSS2-ERG*
Substance Nomenclature :
0 (AR protein, human)
0 (Oncogene Proteins, Fusion)
0 (Receptors, Androgen)
0 (Spike Glycoprotein, Coronavirus)
0 (TMPRSS2-ERG fusion protein, human)
0 (spike protein, SARS-CoV-2)
08J2K08A3Y (Dihydrotestosterone)
EC 3.4.17.23 (ACE2 protein, human)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
EC 3.4.21.- (Serine Endopeptidases)
EC 3.4.21.- (TMPRSS2 protein, human)
Entry Date(s) :
Date Created: 20201210 Date Completed: 20210222 Latest Revision: 20210222
Update Code :
20210223
PubMed Central ID :
PMC7720011
DOI :
10.1016/j.meegid.2020.104669
PMID :
33301988
Czasopismo naukowe
Members of Coronaviridae family have been the source of respiratory illnesses. The outbreak of SARS-CoV-2 that produced a severe lung disease in afflicted patients in China and other countries was the reason for the incredible attention paid toward this viral infection. It is known that SARS-CoV-2 is dependent on TMPRSS2 activity for entrance and subsequent infection of the host cells and TMPRSS2 is a host cell molecule that is important for the spread of viruses such as coronaviruses. Different factors can increase the risk of prostate cancer, including older age, a family history of the disease. Androgen receptor (AR) initiates a transcriptional cascade which plays a serious role in both normal and malignant prostate tissues. TMPRSS2 protein is highly expressed in prostate secretory epithelial cells, and its expression is dependent on androgen signals. One of the molecular signs of prostate cancer is TMPRSS2-ERG gene fusion. In TMPRSS2-ERG-positive prostate cancers different patterns of changed gene expression can be detected. The possible molecular relation between fusion positive prostate cancer patients and the increased risk of lethal respiratory viral infections especially SARS-CoV-2 can candidate TMPRSS2 as an attractive drug target. The studies show that some molecules such as nicotinamide, PARP1, ETS and IL-1R can be studied deeper in order to control SARS-CoV-2 infection especially in prostate cancer patients. This review attempts to investigate the possible relation between the gene expression pattern that is produced through TMPRSS2-ERG fusion positive prostate cancer and the possible influence of these fluctuations on the pathogenesis and development of viral infections such as SARS-CoV-2.
(Copyright © 2020 Elsevier B.V. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies